Literature DB >> 15466925

A case for developing North-South partnerships for research in sickle cell disease.

David Weatherall1, Karen Hofman, Griffin Rodgers, John Ruffin, Sharon Hrynkow.   

Abstract

For a better understanding of the pathophysiology and mechanisms of phenotypic diversity of sickle cell disease, and for the improvement of its management globally, there is a strong case for developing sustainable research partnerships between rich and poor countries.

Mesh：

Year:  2004        PMID： 15466925     DOI： 10.1182/blood-2004-06-2404

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  25 in total

1.  High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya.

Authors:  Charlotte F McAuley; Clare Webb; Julie Makani; Alexander Macharia; Sophie Uyoga; Daniel H Opi; Carolyne Ndila; Antony Ngatia; John Anthony G Scott; Kevin Marsh; Thomas N Williams
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

2.  Subclinical left ventricular systolic impairment in steady state young adult patients with sickle-cell anemia.

Authors:  Nadjib Hammoudi; Dimitri Arangalage; Morad Djebbar; Katia Stankovic Stojanovic; Magali Charbonnier; Richard Isnard; Robert Girot; Pierre-Louis Michel; François Lionnet
Journal:  Int J Cardiovasc Imaging       Date:  2014-06-22       Impact factor: 2.357

3.  Perspective: we need a global solution.

Authors:  Isaac Odame
Journal:  Nature       Date:  2014-11-13       Impact factor: 49.962

4.  Protective BCL11A and HBS1L-MYB polymorphisms in a cohort of 102 Congolese patients suffering from sickle cell anemia.

Authors:  Tite Minga Mikobi; Prosper Tshilobo Lukusa; Michel Ntetani Aloni; Aimé Zola Lumaka; Didine Kinkodi Kaba; Koenraad Devriendt; Gert Matthijs; Jean Marie Mbuyi Muamba; Valérie Race
Journal:  J Clin Lab Anal       Date:  2017-03-23       Impact factor: 2.352

Review 5.  Sickle cell disease in Africa: burden and research priorities.

Authors:  J Makani; T N Williams; K Marsh
Journal:  Ann Trop Med Parasitol       Date:  2007-01

6.  Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Authors:  Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang
Journal:  Blood       Date:  2005-10-01       Impact factor: 22.113

7.  A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11.

Authors:  E Pizzo; A A Laverty; K J Phekoo; G AlJuburi; S A Green; D Bell; A Majeed
Journal:  J Public Health (Oxf)       Date:  2014-05-05       Impact factor: 2.341

Review 8.  Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?

Authors:  Patrick T McGann; Russell E Ware
Journal:  Curr Opin Hematol       Date:  2011-05       Impact factor: 3.284

Review 9.  How I use hydroxyurea to treat young patients with sickle cell anemia.

Authors:  Russell E Ware
Journal:  Blood       Date:  2010-03-11       Impact factor: 22.113

10.  Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease.

Authors:  Christopher J Bean; Sheree L Boulet; Dorothy Ellingsen; Meredith E Pyle; Emily A Barron-Casella; James F Casella; Amanda B Payne; Jennifer Driggers; Heidi A Trau; Genyan Yang; Kimberly Jones; Solomon F Ofori-Acquah; W Craig Hooper; Michael R DeBaun
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.